Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link? DOI Open Access

Marianne Ayoub,

Santos A. Susín, Brigitte Bauvois

et al.

Cancers, Journal Year: 2024, Volume and Issue: 17(1), P. 72 - 72

Published: Dec. 29, 2024

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic CD5+/CD19+ B lymphocytes in blood. These cells migrate to and proliferate bone marrow lymphoid tissues. Despite development new therapies for CLL, drug resistance disease relapse still occur; novel treatment approaches are therefore needed. Inhibition angiogenesis involved progression CLL might be a relevant therapeutic strategy. The literature data indicate that vascular endothelial growth factor, angiopoietin-2, matrix metalloproteinase-9 pro-angiogenic factors CLL. A number other have activity: fibroblast factor-2, certain chemokines (such as CXCL-12 CXCL-2), tumor necrosis factor-α, insulin-like factor-1, neutrophil gelatinase-associated lipocalin, progranulin. All these molecules contribute survival, proliferation, migration cells. Here, we review on factors’ respective expression profiles roles We also summarize main results preclinical clinical trials agents targeting most setting. Through eradication leukemic inhibition angiogenesis, alter course

Language: Английский

siRNA-mediated inhibition of hTERT enhances the effects of curcumin in promoting cell death in precursor-B acute lymphoblastic leukemia cells: an in silico and in vitro study DOI Creative Commons
Muhammad Hossein Ashoub, Ali Afgar, Alireza Farsinejad

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 24, 2025

Language: Английский

Citations

1
The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy DOI Open Access

Haokang Feng,

Jiale Feng, Xu Han

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(2), P. 289 - 289

Published: Jan. 10, 2024

The dysregulation of sialic acid is closely associated with oncogenesis and tumor progression. Most cells exhibit upregulation. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are receptors that recognize expressed in various immune cells. activity Siglecs the microenvironment promotes escape, mirroring mechanisms well-characterized PD-1/PD-L1 pathway cancer. Cancer utilize acid-linked glycans to evade surveillance. As similar as established checkpoint inhibitors (ICIs), they potential therapeutic targets for different forms cancer, especially ICI-resistant malignancies. Additionally, upregulation serves a biomarker. This review examines feasibility using early malignant detection discusses targeting Siglec–sialic interaction novel cancer strategy.

Language: Английский

Citations

6
Extracellular Vesicles in Chronic Lymphocytic Leukemia: Tumor Microenvironment Messengers as a Basis for New Targeted Therapies? DOI Open Access
Kenza Dubois, Mariana Tannoury, Brigitte Bauvois

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(8), P. 2307 - 2307

Published: April 14, 2023

In addition to intrinsic genomic and nongenomic alterations, tumor progression is also dependent on the microenvironment (TME, mainly composed of extracellular matrix (ECM), secreted factors, bystander immune stromal cells). chronic lymphocytic leukemia (CLL), B cells have a defect in cell death; contact with TME secondary lymphoid organs dramatically increases cells' survival via activation various molecular pathways, including receptor CD40 signaling. Conversely, CLL increase permissiveness by inducing changes ECM, cells. Recently, vesicles (EVs) released into emerged as key arbiters cross-talk The EVs' cargo can contain bioactive substances (including metabolites, proteins, RNA, DNA); upon delivery target cells, these induce intracellular signaling drive progression. Here, we review recent research biology EVs CLL. diagnostic/prognostic significance clearly influence clinical outcome CLL; hence, from perspective blocking CLL-TME interactions, are therapeutic targets. identification novel EV inhibitors might pave way development combination treatments for optimization currently available immunotherapy).

Language: Английский

Citations

7
Untargeted metabolomics identifies metabolic dysregulation of sphingolipids associated with aggressive chronic lymphocytic leukaemia and poor survival DOI Creative Commons
Flora Nguyen Van Long,

Délya Valcourt‐Gendron,

Patrick Caron

et al.

Clinical and Translational Medicine, Journal Year: 2023, Volume and Issue: 13(12)

Published: Nov. 30, 2023

Abstract Background Metabolic dependencies of chronic lymphocytic leukaemia (CLL) cells may represent new personalized treatment approaches in patients harbouring unfavourable features. Methods Here, we used untargeted metabolomics and lipidomics analyses to isolate metabolomic features associated with aggressive CLL poor survival outcomes. We initially focused on profiles overexpression the adverse metabolic marker glycosyltransferase (UGT2B17) drug resistance. Results Leukaemic B‐cell metabolomes indicated a significant perturbation lipids, predominantly bio‐active sphingolipids. Expression numerous enzyme‐encoding genes sphingolipid biosynthesis pathways was significantly shorter patient survival. Targeted further exposed higher circulating levels glucosylceramides (C16:0 GluCer) relative healthy donors an cancer biology. In multivariate analyses, C16:0 GluCer sphinganine were independent prognostic markers inversely linked treatment‐free These two species function as antagonistic mediators, being pro‐apoptotic pro‐proliferative, tested leukemic B‐CLL cell models. Blocking synthesis using ceramide glucosyltransferase inhibitors induced death reduced proliferative phenotype, which sensitized leukaemic model anti‐leukaemics fludarabine ibrutinib vitro. Conclusions Specific sphingolipids serve CLL, inhibiting enzymatic involved their has potential therapaeutic approach.

Language: Английский

Citations

7
Dysfunctional cardiac energy transduction, mitochondrial oxidative stress, oncogenic and apoptotic signaling in DiNP-induced asthma in murine model DOI Creative Commons
Samuel Abiodun Kehinde, Abosede Temitope Olajide, Tolulope Peter Fatokun

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 17, 2024

Language: Английский

Citations

2
CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: from interconnected signalling pathways to therapeutic strategies DOI
Brigitte Bauvois, Florence Nguyen‐Khac, Hélène Merle‐Béral

et al.

Biochimie, Journal Year: 2024, Volume and Issue: unknown

Published: July 1, 2024

Language: Английский

Citations

1
The Value of Neutrophil Gelatinase-Associated Lipocalin Receptor as a Novel Partner of CD38 in Chronic Lymphocytic Leukemia: From an Adverse Prognostic Factor to a Potential Pharmacological Target? DOI Creative Commons
Brigitte Bauvois, Élise Chapiro, Claire Quiney

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(9), P. 2335 - 2335

Published: Aug. 22, 2023

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic B lymphocytes that escape death, and correlates with expression negative prognostic markers such as CD38 antigen. Although certain new drugs approved US Food Drug Administration improve clinical outcome CLL patients, drug resistance disease relapse still occur. Like CD38, neutrophil gelatinase-associated lipocalin receptor (NGAL-R) frequently overexpressed in cells. Here, we evaluated concomitant surface NGAL-R leukemic blood cells from 52 patients (37 untreated, 8 remission, 7 relapsed). We provide evidence a positive correlation between levels both interpatient cohorts (p < 0.0001) individual indicating constitutive association at cell level. Patients progressing showed time-dependent increase NGAL-R/CD38 levels. In treated who achieved were decreased, significantly lower than untreated relapsed groups 0.02). As participate survival, envisioning their simultaneous inhibition bispecific antibodies capable inducing death might therapeutic benefit for patients.

Language: Английский

Citations

3
Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link? DOI Open Access

Marianne Ayoub,

Santos A. Susín, Brigitte Bauvois

et al.

Cancers, Journal Year: 2024, Volume and Issue: 17(1), P. 72 - 72

Published: Dec. 29, 2024

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic CD5+/CD19+ B lymphocytes in blood. These cells migrate to and proliferate bone marrow lymphoid tissues. Despite development new therapies for CLL, drug resistance disease relapse still occur; novel treatment approaches are therefore needed. Inhibition angiogenesis involved progression CLL might be a relevant therapeutic strategy. The literature data indicate that vascular endothelial growth factor, angiopoietin-2, matrix metalloproteinase-9 pro-angiogenic factors CLL. A number other have activity: fibroblast factor-2, certain chemokines (such as CXCL-12 CXCL-2), tumor necrosis factor-α, insulin-like factor-1, neutrophil gelatinase-associated lipocalin, progranulin. All these molecules contribute survival, proliferation, migration cells. Here, we review on factors’ respective expression profiles roles We also summarize main results preclinical clinical trials agents targeting most setting. Through eradication leukemic inhibition angiogenesis, alter course

Language: Английский

Citations

0